Literature DB >> 33272351

A cautionary note on using Mendelian randomization to examine the Barker hypothesis and Developmental Origins of Health and Disease (DOHaD).

Shannon D'Urso1, Geng Wang1, Liang-Dar Hwang1, Gunn-Helen Moen1,2,3,4, Nicole M Warrington1,3, David M Evans1,5.   

Abstract

Recent studies have used Mendelian randomization (MR) to investigate the observational association between low birth weight (BW) and increased risk of cardiometabolic outcomes, specifically cardiovascular disease, glycemic traits, and type 2 diabetes (T2D), and inform on the validity of the Barker hypothesis. We used simulations to assess the validity of these previous MR studies, and to determine whether a better formulated model can be used in this context. Genetic and phenotypic data were simulated under a model of no direct causal effect of offspring BW on cardiometabolic outcomes and no effect of maternal genotype on offspring cardiometabolic risk through intrauterine mechanisms; where the observational relationship between BW and cardiometabolic risk was driven entirely by horizontal genetic pleiotropy in the offspring (i.e. offspring genetic variants affecting both BW and cardiometabolic disease simultaneously rather than a mechanism consistent with the Barker hypothesis). We investigated the performance of four commonly used MR analysis methods (weighted allele score MR (WAS-MR), inverse variance weighted MR (IVW-MR), weighted median MR (WM-MR), and MR-Egger) and a new approach, which tests the association between maternal genotypes related to offspring BW and offspring cardiometabolic risk after conditioning on offspring genotype at the same loci. We caution against using traditional MR analyses, which do not take into account the relationship between maternal and offspring genotypes, to assess the validity of the Barker hypothesis, as results are biased in favor of a causal relationship. In contrast, we recommend the aforementioned conditional analysis framework utilizing maternal and offspring genotypes as a valid test of not only the Barker hypothesis, but also to investigate hypotheses relating to the Developmental Origins of Health and Disease more broadly.

Entities:  

Keywords:  Barker hypothesis; Developmental Origins of Health and Disease; Mendelian randomization; cardiometabolic disease; causal inference; conditional analysis; type 2 diabetes

Mesh:

Year:  2020        PMID: 33272351     DOI: 10.1017/S2040174420001105

Source DB:  PubMed          Journal:  J Dev Orig Health Dis        ISSN: 2040-1744            Impact factor:   2.401


  5 in total

Review 1.  Parental overnutrition by carbohydrates in developmental origins of metabolic syndrome.

Authors:  O Šeda
Journal:  Physiol Res       Date:  2021-12-30       Impact factor: 2.139

Review 2.  Low Birthweight as a Risk Factor for Non-communicable Diseases in Adults.

Authors:  Maria Eugenia Bianchi; Jaime M Restrepo
Journal:  Front Med (Lausanne)       Date:  2022-01-06

3.  Investigating a Potential Causal Relationship Between Maternal Blood Pressure During Pregnancy and Future Offspring Cardiometabolic Health.

Authors:  Geng Wang; Laxmi Bhatta; Gunn-Helen Moen; Liang-Dar Hwang; John P Kemp; Tom A Bond; Bjørn Olav Åsvold; Ben Brumpton; David M Evans; Nicole M Warrington
Journal:  Hypertension       Date:  2021-11-17       Impact factor: 10.190

4.  Birthweight, BMI in adulthood and latent autoimmune diabetes in adults: a Mendelian randomisation study.

Authors:  Yuxia Wei; Yiqiang Zhan; Josefin E Löfvenborg; Tiinamaija Tuomi; Sofia Carlsson
Journal:  Diabetologia       Date:  2022-05-23       Impact factor: 10.460

5.  Both indirect maternal and direct fetal genetic effects reflect the observational relationship between higher birth weight and lower adult bone mass.

Authors:  Jiang-Wei Xia; Lin Zhang; Jin Li; Cheng-Da Yuan; Xiao-Wei Zhu; Yu Qian; Saber Khederzadeh; Jia-Xuan Gu; Lin Xu; Jian-Hua Gao; Ke-Qi Liu; David Karasik; Shu-Yang Xie; Guo-Bo Chen; Hou-Feng Zheng
Journal:  BMC Med       Date:  2022-10-04       Impact factor: 11.150

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.